Background: Endometrial neoplasms is one of the most typical gynecologic diseases with harmful effects. Promoter hypermethylation is an important mechanism of the inactivation of tumor suppressor genes in endometrial neoplasms. Epigenetic changes of the PTEN and APC genes have shown to be present in various cancers. Therefore, in this study, we have investigated the association between the promoter hypermethylation of PTEN and APC genes with endometrial neoplasms. Methods: For this study, 28 patients with endometrial neoplasms as well as 22 controls were studied. Analysis of the promoter methylation regions of PTEN and APC genes were performed by Methylation-Specific PCR. Results: The frequency of PTEN and APC genes promoter methylation was 28.57% and 17.86% in tumor tissues, and 11.54% and 3.85% in blood samples, respectively. We found a significant relationship between blood and tissue in PTEN methylation (p = 0.0353). Additionally, we determined a closely significant difference between normal tissue and tumor tissue of the PTEN gene (p = 0.0787) and blood and tissue samples of the APC gene in methylated promoter regions (p=0.0623). Furthermore, these results suggest that there is no significant relationship between the promoter methylation of PTEN and APC with clinical characteristics. Conclusion: DNA methylation deficiency is a well known highlighted factor in tumorigenesis, therefore the promoter hypermethylation of PTEN and APC can be indicated as a risk factor in endometrial neoplasms.
Introduction
One of the most common forms of cancers in females, which is usually recognized at early stages, is endometrial cancer (EC) (Markowska et al., 2014) . Collected information has revealed that the prevalence of endometrial cancer with stage I and II was 73% and 10%, respectively (Trimble et al., 2005; Creasman et al., 2006) . There are two variants of endometrial cancer with diversity in their clinicopathologic features. Type I tumors (endometrioid caners) are completely differentiated and estrogen-related. On the other hand, type II tumors (non-endometrioid cancers) are non-estrogen-related (Tao and Freudenheim, 2010) . Major risk factors in endometrial cancer include the estrogen element, mismatch repair disorders, microsatellite instability, and epigenetic variation (Banno et al., 2014; Mutter et al., 1996) . Similar to other types of cancer, endometrial carcinoma can be caused by the aggregation of genetic mutations (Feng et al., 2012) .
Genomic DNA methylation depends on the addition of methyl groups at CpG sites by DNA methyltransferase.
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The adenomatous polyposis coli (APC) is a tumor suppressor gene that is located in 5q21-22 (Aoki and Taketo, 2007) . Alterations of the APC gene has been reported in 80% of colon cancers (Powell et al., 1992; Nagase and Nakamura, 1993) . The Wnt pathway is regulated by mutations in the APC and β-catenin genes that are also correlated with endometrial cancer (Schlosshauer et al., 2000; Kobayashi et al., 1999) . Hypermethylation of the APC promoter has been reported in 20-45% of endometrial cancers (Banno et al., 2006; Yang et al., 2006) . APC is shown to moderate β-catenin levels, whereas, inhibition of APC expression will lead to an increase in the levels of β-catenin, which induces the Wnt signaling pathway and eventually increases the transcriptional activity (Fearnhead et al., 2001; Behrens et al., 1996) . The purpose of the present study is to evaluate the association between PTEN and APC promoter hypermethylation with endometrial cancer in the blood and tissue samples in endometrial cancer patients. Also, we aim to investigate the correlation between endometrial cancer and distinct clinical characteristics.
Materials and Methods
Research population
Twenty eight cancerous tissues along with associated clinopathological parameters and twenty six blood samples of the same individual with endometrial cancer were collected from patients who had been referred to the Mahdiyeh Hospital (Tehran, Iran), Firuzgar Hospital (Tehran, Iran), Kowsar Hospital (Ghazvin, Iran), and Pastour Hospital (Ghazvin, Iran), between 2014 and 2016. In addition, twenty-two normal tissues were sampled as the control group. Informed consent was signed by the patients. The average age was 65.5 years for both groups (range, 38-76 years) . None of the patients had received chemotherapy. They were examined in the Biology Research Center of Islamic Azad University, Zanjan (Iran).The clinical diagnosis of endometrial cancer was in accordance with the criteria of the International Federation of Gynecology and Obstetrics (FIGO).The clinicopathologic traits were diagnosed by experted gynecologists.
DNA isolation and methylation-specific PCR
Tissue samples were cut into 10 μm segments and used for DNA isolation (Cat.NO.180134, QIAGEN Inc, Valencia, CA) and also genomic DNA was extracted from EDTA-blood samples using the cinnaClon Genomic DNA purification Kit (Cat.No.PR881612) following the manufacturer's instructions. Sodium bisulfite converts unmethylated cytosine to uracil. The effects of bisulfite were performed by the CpG genome DNA Modification Kit (Cat.No.59104, QIAGEN Inc, Valencia, CA) (Yari et al., 2016) . Afterwards, the buffer BL/carrier RNA solution was used to increase extracted DNA levels (Cat. No.59104, QIAGEN Inc, Valencia, CA ) (Gravina et al., 2015) . Forward and reverse primers were designed for unmethylated and methylated promoter regions by Gene runner and meth primer software after obtaining gene sequences from Gene Bank (http://www.ncbi.nlm. nih.gov). The primer sequences are shown in Table 1 . Amplification was carried by gradient PCR, using a model of PCR gradient thermo cycler (Eppendorf, Germany). MSP amplification was performed in a final volume of 20 μL containing 1X PCR Master Mix (CinnaGen PCR Master Mix, Iran), 50 ng of template bisulfite converted DNA, and 10 pmol of forward and reverse primers each (Gen Fanavaran, Iran). MSP amplifications was performed as follows: the first denaturation cycle of DNA at 95°C for 5 min followed by 34 cycles, each consisting of 45 s denaturation at 95°C, 45 s annealing at 59°C for PTEN (M), 57°C for PTEN (U), 54°C for APC (M), 57°C for APC (U), and 45 s extension at 72°C, with the final extension cycle of 72°C for 5 min. The PCR products were analyzed by the electrophoresis of agarose gel (2.5% agarose), stained with DNA safe stain and visualized by a UV transilluminator. For MSP confirmation and correct determination of methylated, hemimethilated, and non methylated genotypes, modified genomic DNA samples from regulatory CpG islands of both normal endometrium and cancerous tissue were analyzed by sequencing for both PTEN and APC genes.
Statistical analysis
The statistical comparison was calculated by Pearson's chi-square. The data analysis was performed by SPSS20. P-values <0.05 were statistically significant. The rates of odds ratio and 95% confidence intervals were assayed by logistic regression.
Results
Determination of clinicopathological features
The samples consisted of 25 endometrioid carcinomas [endometrial adenocarcinoma:19 FIGO grade 1 (stage IA, IB), 4 FIGO grade 2, 2 FIGO grade 3 (IIIB)], and 3 nonendometrioid carcinomas [serous papillary :3 FIGO grade 3 (stage IIIA)]. Nine of twenty-five (36%) endometrioid carcinomas showed metastasis. In addition, nonendometrioid carcinomas lacked signs of any metastasis.
Analysis of promoter methylation in PTEN and APC genes
Methylation specific PCR was used to assay the role of the methylation status of PTEN and APC promoters in endometrial cancer. The frequencies of PTEN and APC methylation in promoter regions have been shown in Table 2 . Hypermethylation of PTEN was observed in 28.57% of tumor tissues and 4.54% of normal tissues (Figure 1, 3) . The results were closely linked to being statistically significant between tumor tissues and normal tissues (OR=2.0765, 95% CI [0.9197-4.6887], p = 0.0787) ( Table 2 ). There was a significant increase of PTEN methylation in patients' blood (11.54%) compared to tumor tissues (28.57%). There was a significant difference in the methylation of the PTEN promoter between the patients' blood and tumor tissues (OR=2.4377, 95% CI [1.0635-5.5876], p = 0.0353) ( Table 2 ). Promoter methylation of the APC gene between tumor tissues and patients' blood is statistically significant (OR=0.4047, 95% CI [0.1563-1.0476] , p=0.0623) ( Table 2 ). The association between the methylation of PTEN and APC promoters with clinicopathological features was analyzed in the endometrial cancer. We found no significant correlations between clinicopathological features, including age, tumor grade, tumor stage, histologic type, depth of myometrial was shown in the APC gene in 17.86% of tumor tissues and 4.55% of normal tissues (Figure 2, 3) . The study showed that APC methylation was not significantly correlated between tumor tissues and normal tissues (OR=0.7073, 95% CI [0.2995-1.6703] , p = 0.4296) ( Table  2) . Among the patients' blood, the frequency of promoter methylation in the APC gene was 3.85% (Figure 2, 3) . Results indicate that the promoter methylation analysis invasion, and metastasis in endometrial cancer (P>0.05) ( Table 3 ). In addition, the correlation between promoter hypermethylation of the PTEN and APC genes with clinical characteristics, including diabetes, high weight, high blood pressure, and menstrual disorder was evaluated.
Results show there was no significant difference between clinical characteristics and promoter hypermethylation of the PTEN and APC genes in endometrial cancer (P>0.05) ( Table 4) .
Discussion
Aberrant DNA hypermethylation of tumor-suppressor genes is a prevalent molecular change in the early stages of cancers and it can be highlighted as a biomarker in the detection and treatment of tumors (laird., 2003) . Epigenetic deficiencies with promoter hypermethylation have an important role in the inactivation of tumor suppressor genes in cancer (Salvesen et al., 2001 in blood and bodily fluids, furthermore, the availability of patients' blood is more convenient compared to tumor tissues (Nagrath et al., 2007; Sharma et al., 2007) . For this study, both blood and tissue samples were selected. Hemi-methylated promoter regions of PTEN was 88.46% in patients' blood, 46.43% in tumor tissues and methylated regions were 11.54% and 28.57% in patients' blood and tumor tissues, respectively. The results indicated that the frequency of hemi-methylated regions was higher than methylated regions. Our findings support a significant difference in the promoter methylation of the PTEN gene in the patients' blood and normal tissues (p = 0.0353). In contrast, the methylated promoter region of APC was 3.85% and 17.86% in patients' blood and tumor tissues, respectively and no significant difference was observed in patients' blood (p = 0.0623) and tumor tissues (p=0.4296). This discrepancy might be due to environmental effects and sample size. PTEN promoter hypermethylation is a broadly studied genetic mutation in endometrial cancer (Salvesen et al., 2001) . Gao et al., (2009) reported that the expression of PTEN has decreased during the progression of endometrial cancer (Ρ<0.01). They showed that PTEN expression is correlated to the tumor stage, tumor grade, and histologic type (P<0.05), but there was no significant difference in the depth of myometrial invasion (P>0.05).
In our study, we observed a significant increase in the hypermethylation of PTEN in patients' blood. We found no relationship between clinicopathological features and endometrial cancer. Zuberi et al., (2014) showed that the frequency of PTEN promoter hypermethylation was 16% in the blood of patients with ovarian cancer and there was no significant difference in the PTEN methylation of the promoter between patients and controls (p=0.09). They found no significant correlations between clinicopathological features, including age, tumor stage, and histologic type, and patients type (P>0.05).
In our estimate, the prevalence of PTEN methylation was 11.54% and 28.57% in patients' blood and tumor tissues, respectively. QI et al., (2014) showed that the frequency of PTEN promoter hypermethylation was 62% in tumor tissues of patients with cervical cancer where the methylation of the PTEN promoter was significantly related to the tumor grade, metastasis, and tumor stage (P<0.05). They found a significant association between the promoter methylation of PTEN and cervical cancer (P=0.042). They also suggested that promoter hypermethylation could be a key mechanism of PTEN inactivation in cervical cancer. We found a meaningful association between the hypermethylation of the PTEN promoter and endometrial cancer in patients' blood. The APC/β-catenin pathways were initially reported in the field of endometrial cancer (Aoki and Taketo, 2007; Moreno-Bueno et al., 2002) . Guo et al., (2014) Table 4 . Association between Clinical Characteristics of the Study Groups with Eendometrial Cancer no significant relationship between clinicopathological features and APC methylation (P>0.05). Based on our study, promoter hypermethylation of APC and PTEN genes may be a biomarker in the diagnosis of endometrial cancer. More studies with larger populations and a suitable election of the case-control study will be essential to understand the role of hypermethylation of the APC and PTEN genes as biomarkers in endometrial cancer. I n c o n c l u s i o n , p r o m o t e r m e t h y l a t i o n o f tumor-suppressor genes is a typical epigenetic change in endometrial cancer. Hypermethylation of PTEN and APC in the promoter region may have a significant effect in the development of endometrial cancer. In our study, there was a significant relationship between blood and tissue in PTEN methylation (OR=2.4377, 95% CI [1. 0635-5.5876 
